China NT Pharma : VOLUNTARY ANNOUNCEMENT SHUSI APPROVED IN CONSISTENCY EVALUATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to the accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011)

VOLUNTARY ANNOUNCEMENT

SHUSI APPROVED IN CONSISTENCY EVALUATION

This announcement is made by the board of directors (the "Board") of China NT Pharma Group Company Limited (the "Company", and together with its subsidiaries, the "Group") on a voluntary basis.

Shusi (generic name: quetiapine fumarate) ("Shusi"), a compound medicine of our subsidiary 蘇州第壹製藥有限公司 (Suzhou First Pharmaceutical Co., Ltd.) ("Suzhou First") used for the treatment of bipolar affective disorder, has recently been approved in the Consistency Evaluation (the "Consistency Evaluation") of the China Food and Drug Administration . The product is a generic drug that has completed the bioequivalence study in accordance with the "Consistency of Quality and Efficacy Evaluation for Generic Drugs" standard and passed the head-to-head comparison clinical trials with the original drug, which proves that the drug and the original drug are identical in terms of quality and efficacy and indicates that it can be used as a clinical alternative for the original drug and provides a medication option of good quality and competitive price for patients.

Shusi is a proprietary product of Suzhou First. In December 2013, it was approved by the China Food and Drug Administration for the treatment of bipolar affective disorder. Shusi is an atypical antipsychotic drug which has proven safety track records and therapeutic effects on first-time psychiatric patients, elderly patients and adolescent patients. As a drug listed on both the National Reimbursement Drug List and the National Essential Drugs List, Shusi is a state approved prescription medicine. The approval of Shusi, a proprietary product of the Group, in the Consistency Evaluation would further strengthen the Group's market position in psychiatric treatment in China.

By Order of the Board

China NT Pharma Group Company Limited

Ng Tit

Chairman

Hong Kong, 20 February 2020

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Dr. Hong Yan and Dr. Zhao Yubiao.